12:55 PM EDT, 06/13/2024 (MT Newswires) -- Cardiol Therapeutics ( CRDL ) shares were down 16.5% in recent Thursday trading after the company reported eight-week phase 2 clinical data for CardiolRx to treat patients with symptomatic recurrent pericarditis.

The clinical-stage life sciences company said CardiolRx, an oral cannabidiol solution, showed "a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment."

The trial enrolled 27 adult participants with symptomatic recurrent pericarditis, and the treatment was deemed safe and generally well-tolerated, the company said.

Price: 2.48, Change: -0.49, Percent Change: -16.50